

# The Medical Letter<sup>®</sup>

## on Drugs and Therapeutics

Volume 60

June 18, 2018

ISSUE No.

1549

### IN THIS ISSUE

In Brief: Another Insulin Lispro (*Admelog*) for Diabetes ..... online

## Important Copyright Message

### FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)  
or call customer service at: 800-211-2769

# The Medical Letter<sup>®</sup>

## on Drugs and Therapeutics

Volume 60 (Issue 1549)

June 18, 2018

### IN BRIEF

#### Another Insulin Lispro (*Admelog*) for Diabetes

The FDA has approved *Admelog* (Sanofi-Aventis), an insulin lispro product similar to *Humalog* (Lilly), which went off patent in 2013.

Approval of *Admelog* was based on efficacy data with *Humalog* and on two 6-month, open-label, randomized, noninferiority trials. In SORELLA 1<sup>1</sup> in 507 patients with type 1 diabetes and SORELLA 2<sup>2</sup> in 505 patients with type 2 diabetes, *Admelog* was noninferior to *Humalog* in lowering A1C, fasting plasma glucose levels, and self-monitored plasma glucose levels. The incidence of adverse effects, including hypoglycemia, was similar.

Table 1. Insulin Lispro Products

Drug	Concentration	Some Formulations	Cost <sup>1</sup>
<i>Humalog</i> (Lilly)	100 units/mL,	3, 10 mL vials	\$274.70
	200 units/mL <sup>2</sup>	3 mL <i>KwikPen</i> <sup>3</sup>	106.10
<i>Admelog</i> (Sanofi-Aventis)	100 units/mL	10 mL vials	233.50
		3 mL <i>SoloStar</i> pen <sup>4</sup>	90.20

1. Approximate WAC for one 10-mL vial or one 100 unit/mL 3-mL pen. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers. WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource@ Monthly. June 5, 2018. Reprinted with permission by First Databank, Inc. All rights reserved. ©2018. [www.fdbhealth.com/policies/drug-pricing-policy](http://www.fdbhealth.com/policies/drug-pricing-policy).

2. Only the *KwikPen* is available in a concentration of 200 units/mL.

3. Long-acting insulin glargine (*Basaglar*) is also available in a *Kwikpen*.

4. Long-acting insulin glargine (*Lantus*) is also available in a *SoloStar* pen.

Even though *Admelog* is very similar to *Humalog* in composition, strength, and structural and biological properties, and appears to produce the same glucose-lowering effects, it was not designated as a biosimilar or an interchangeable biologic product by the FDA because of a regulatory technicality: insulin is classified as a chemical, not a biological, entity, so there is no biologic reference product for insulin lispro. Pharmacists cannot substitute *Admelog* for *Humalog* without the permission of the prescriber.

*Admelog* is available in 10-mL vials and in packages of five multi-dose *SoloStar* pens, each prefilled with 3 mL of insulin lispro 100 units/mL. A pen can deliver 1 to 80 units per injection. It should be primed with 2 units of insulin lispro before each injection. *Admelog* should be injected subcutaneously within 15 minutes before a meal, or immediately after a meal.

*Admelog* is similar to *Humalog* in efficacy and safety. Patients could use either one. ■

1. SK Garg et al. Efficacy and safety of biosimilar SAR342434 insulin lispro in adults with type 1 diabetes also using insulin glargine – SORELLA 1 study. *Diabetes Technol Ther* 2017; 19:516.

2. KM Derwahl et al. Efficacy and safety of biosimilar SAR342434 insulin lispro in adults with type 2 diabetes, also using insulin glargine: SORELLA 2 study. *Diabetes Technol Ther* 2018; 20:49.

**PRESIDENT:** Mark Abramowicz, M.D.; **VICE PRESIDENT AND EXECUTIVE EDITOR:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School; **EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D.; **CONSULTING EDITORS:** Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

**CONTRIBUTING EDITORS:** Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Franco M. Muggia, M.D., New York University Medical Center; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; F. Estelle R. Simons, M.D., F.R.C.P.C., F.R.S.C., University of Manitoba; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

**MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS:** Susie Wong; **ASSISTANT MANAGING EDITOR:** Liz Donohue

**FULLFILLMENT AND SYSTEMS MANAGER:** Cristine Romatowski; **SITE LICENSE SALES:** Elaine Reaney-Tomaselli; **EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS:** Joanne F. Valentino; **VICE PRESIDENT AND PUBLISHER:** Yosef Wissner-Levy

Founded in 1959 by  
Arthur Kallet and Harold Aaron, M.D.

**Copyright and Disclaimer:** The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

#### Subscription Services


**Address:**  
The Medical Letter, Inc.  
145 Huguenot St. Ste. 312  
New Rochelle, NY 10801-7537  
www.medicalletter.org

**Customer Service:**  
Call: 800-211-2769 or 914-235-0500  
Fax: 914-632-1733  
E-mail: custserv@medicalletter.org

**Permissions:**  
To reproduce any portion of this issue,  
please e-mail your request to:  
permissions@medicalletter.org

**Subscriptions (US):**  
1 year - \$159; 2 years - \$298;  
3 years - \$398. \$65 per year  
for students, interns, residents, and  
fellows in the US and Canada.  
Reprints - \$25/article; \$35/issue

**Site License Inquiries:**  
E-mail: SubQuote@medicalletter.org  
Call: 800-211-2769  
Special rates available for bulk  
subscriptions.

Get Connected:  

Copyright 2018. ISSN 1523-2859

The  
Medical  
Letter